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Immunocompromised patients are at risk for disease 
caused by infection by some polyomaviruses. To defi ne 
the prevalence of polyomaviruses in children undergoing 
transplantation, we collected samples from a longitudinal 
cohort and tested for the 9 known human polyomaviruses. 
All were detected; several were present in previously 
unreported specimen types.
BK and JC polyomaviruses (BKPyV, JCPyV) cause disease in immunocompromised persons. Both are 
double-stranded DNA viruses in the family Polyomaviridae. 
Seven additional human polyomaviruses were discovered 
during 2007–2011: KI polyomavirus (KIPyV) (1), WU 
polyomavirus (WUPyV) (2), Merkel cell polyomavirus 
(MCPyV) (3), human polyomavirus 6 (HPyV6) (4), human 
polyomavirus 7 (HPyV7) (4), trichodysplasia spinulosa-
associated polyomavirus (TSPyV) (5), and human 
polyomavirus 9 (HPyV9) (6).
The 7 novel polyomaviruses have been detected in 
various specimen types; detection has been extensively 
reviewed for KIPyV, WUPyV, and MCPyV (7). 
Polyomaviruses HPyV6, HPyV7, TSPyV, and HPyV9 
have been detected in skin (4,5,8); TSPyV and HPyV9 
have also been detected in urine, and HPyV9 was detected 
in serum (6). However, only 2 of these recently identifi ed 
viruses have been specifi cally implicated in human 
diseases; MCPyV is associated with Merkel cell carcinoma 
(3), and TSPyV has been linked to trichodysplasia 
spinulosa (5). Immunosuppression is a likely cofactor in 
both diseases. The potential pathogenicity of the other 5 
novel polyomaviruses is unknown. As a fi rst step toward 
exploring their disease potential, we sought to defi ne their 
prevalence in immunocompromised transplant recipients. 
To this end, we established a longitudinal cohort of 
children undergoing transplantation at St. Louis Children’s 
Hospital, St. Louis, Missouri, USA.
The Study
We recruited 32 patients who were scheduled to 
receive transplants (2 lung, 11 liver, 5 heart, 2 kidney, 
1 liver/lung, and 11 bone marrow transplants) during 
October 2008–April 2010. The Human Research Protection 
Offi ce of Washington University in St. Louis approved 
this study. The mean age of enrolled patients was 5.8 
years, and the median age was 3.1 years. Thirty patients 
received transplants and were studied for 1 year after 
transplantation. We collected 716 clinical specimens (160 
nasopharyngeal swab, 169 urine, 122 fecal, 265 plasma) 
during 265 patient visits. We collected 298 specimens from 
patients during symptomatic episodes, which were defi ned 
as having >1 of the following: fever, respiratory symptoms, 
or gastrointestinal symptoms. We collected clinical data 
using a questionnaire and the medical records.
Fecal material was diluted 1:6 in phosphate-buffered 
saline and fi ltered through 0.45-μm membranes. For 
all specimens, we extracted total nucleic acids using an 
Ampliprep Cobas extractor (Roche, Branchburg, NJ, USA). 
We used published real-time PCRs for WUPyV (9), KIPyV 
(9), TSPyV (5), MCPyV (10), BKPyV (11), and JCPyV 
(12) (Table 1). We developed assays for HPyV6, HPyV7, 
and HPyV9 using Primer Express software (Applied 
Biosystems, Carlsbad, CA, USA) (Table 1). To assess the 
performance of each assay, we used serial dilutions (5 to 
5 × 106 copies/reaction) of a plasmid containing the target 
sequence. All 3 assays demonstrated a sensitivity of ≈5 
copies/reaction and yielded linear curves with R2 values 
>0.99.
Each of the 25-μl quantitative PCRs included 5 μL of 
extracted sample, 12.5 pmol of each primer, and 4 pmol 
of probe. The MCPyV primers and probe were used as 
described (10). We tested samples in a 96-well plate format, 
with 8 water negative controls and 1 positive control/plate. 
Reactions were cycled as recommended using either an 
ABI 7500 real-time thermocycler (Applied Biosystems) or 
a CFX96 real-time thermocycler (BioRad, Hercules, CA, 
USA). The threshold of all plates was set at a standard 
value, and samples were counted as positive if their cycle 
threshold was <37.00.
All 716 specimens were tested for each virus (Table 2). 
The most frequently detected virus was BKPyV, which was 
found primarily in urine as expected. JCPyV was detected 
in 1 plasma sample. HPyV6, HPyV7, MCPyV, and TSPyV 
were detected in specimen types not previously reported. 
HPyV6 and TSPyV were detected in fecal samples and 
DISPATCHES
1676 Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 18, No. 10, October 2012
Author affi liation: Washington University School of Medicine, St. 
Louis, Missouri, USA
DOI: http://dx.doi.org/10.3201/eid1810.120359
Polyomaviruses in Children Undergoing Transplantation
nasopharyngeal swab samples, and HPyV7 was detected 
in a nasopharyngeal swab and urine. One fecal sample 
was positive for MCPyV. Because HPyV6, HPyV7, and 
MCPyV have been previously detected in skin, we cannot 
rule out the possibility that their presence in specimens 
could have been caused by shedding from skin.
We collected 2 serial nasopharyngeal samples that 
were positive for KIPyV from patient 3001 (Table 2), 
a 1-year-old child who had received a bone marrow 
transplant as treatment for Fanconi anemia. The fi rst 
sample, a nasopharyngeal swab obtained 1 month after 
transplant, had low levels of KIPyV. To determine the 
viral load of the second nasopharyngeal swab specimen 
collected 2 months later, we reanalyzed the sample in 
triplicate; on the basis of extrapolation of the standard 
curve run in parallel, we estimated the viral load to 
be 1.3 × 109 genome copies/mL of nasopharyngeal 
swab transport media. This patient’s course was 
complicated by graft-versus-host disease of the gut 
and skin, renal failure requiring dialysis, and recurrent 
pulmonary hemorrhage. The patient was critically ill 
and had experienced multiorgan failure at the time of 
the second sampling. Other microbiological test results 
were negative at that time, including PCR for Epstein-
Barr virus, cytomegalovirus, human herpesvirus-6, and 
adenovirus in the blood; aspergillus antigen detection in 
blood; and bacterial cultures of blood, tracheal aspirate, 
urine, and peritoneal fl uid. The fecal specimen collected 
at this time was negative for KIPyV; plasma and urine 
were not available for this study. The patient died of acute 
respiratory failure and extensive pulmonary hemorrhage 
24 days after collection of this specimen. Despite the 
frequent detection of KIPyV in respiratory specimens, no 
studies have defi nitively linked infection with respiratory 
disease. Titers of KIPyV were high in the nasopharyngeal 
swab sample from this patient 3 weeks before respiratory 
failure. Although this observation does not necessarily 
implicate KIPyV infection as a contributing factor in the 
death of the patient, it suggests a poorly controlled KIPyV 
infection in the respiratory tract.
Three specimens collected from patient 4001, a 
13-year-old heart transplant recipient, were positive for 
TSPyV (Figure), but the patient did not have trichodysplasia 
spinulosa. At 1 week after transplant, the nasopharyngeal 
swab and fecal samples were positive for TSPyV. At 1 
month after transplant, the nasopharyngeal swab sample 
was again positive for TSPyV, with a viral load of ≈2.3 
× 104 genome copies/mL of transport media. There is 
currently only 1 TSPyV sequence in GenBank (accession 
no. GU989205). We used 4 primer pairs to amplify the 
complete genome of TSPyV from the nasopharyngeal swab 
taken 1 month after transplant. PCR products were cloned, 
and the complete genome was sequenced to 3× coverage 
(GenBank accession no. JQ723730) and compared with the 
other TSPyV sequence. There were 5 nt substitutions: 3 in 
noncoding regions and 2 synonymous mutations.
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Table 1. Real-time PCR assays to detect human polyomaviruses in children undergoing transplants, United States, 2008–2010* 
Virus Target Primers, 5ƍ o 3ƍ Probe, 5ƍ o 3ƍ 
WUPyV NCCR WU-C-4824-F: GGCACGGCGCCAACT WU-C-4861-TM: FAM-
TGCCATACCAACACAGCTGCTGAGC-TAMRA-3ƍ WU-C-4898-R: 
CCTGTTGTAGGCCTTACTTACCTGTA 
KIPyV LTAg KI-B-4603-F: GAATGCATTGGCATTCGTGA KI-B-4632-TM: FAM-
TGTAGCCATGAATGCATACATCCCACTGC-TAMRA KI-B-4668-R: 
GCTGCAATAAGTTTAGATTAGTTGGTGC 
TSPyV LTAg LTF: TGTGTTTGGAAACCAGAATCATTTG LTP: FAM-TTCTTCTTCCTCCTCATCCTCCACCTCAAT-
TAMRA LTR: TGCTACCTTGCTATTAAATGTGGAG 
MCPyV LTAg LT.1F: CCACAGCCAGAGCTCTTCCT LT probe: FAM-TCCTTCTCAGCGTCCCAGGCTTCA-
TAMRA LT.1R: TGGTGGTCTCCTCTCTGCTACTG 
HPyV6 VP1 ES011F: GCCTGGAAGGGCCTAGTAAAG ES024: FAM-
ACCAACCATCTGTTGCAGGCATTAAAGCTA-TAMRA ES012R: 
ATTGGCAGCTGTAACTTGTTTTCTG 





HPyV9 LTAg ES026F: GAAGACCCTGATCCTGAGGAAGA ES031: FAM-TGGATCATCCCAGAGTTCATTTACCTGCA-
TAMRA ES027R: 
CTCTGGAGTATTAGGTTCAGGCTTCT 










TAMRA JL1 (R): 
TCTAGCCTTTGGGTAACTTCTTGAA 
*WUPyV, WU polyomavirus; NCCR, non-coding control region; KIPyV, KI polyomavirus; LTAg, large T antigen; TSPyV, trichodysplasia spinulosa 
polyomavirus; MCPyV, Merkel cell polyomavirus; HPyV, human polyomavirus; VP, virion protein; BKPyV, BK polyomavirus; JCPyV, JC polyomavirus. 
Although serologic studies have demonstrated that 
≈70% of adults in Europe have been infected by TSPyV 
(13), its mode of transmission is unknown. The detection 
of TSPyV in nasopharyngeal swab and fecal samples raises 
the possibility that it may be transmitted by a respiratory 
or fecal–oral route. Furthermore, in the current study, 2 
sequential nasopharyngeal swab samples taken 20 days 
apart were positive for TSPyV, suggesting it may persist 
for extended periods in the respiratory tract, at least in 
immunosuppressed persons.
Conclusions
Our goals were to establish a longitudinal repository 
of different specimen types from transplant recipients 
and to defi ne the prevalence of polyomaviruses in these 
patients. We detected all 9 polyomaviruses in at least 1 
specimen. Although the prevalence of each virus was 
generally low, TSPyV, HPyV6, HPyV7, and MCPyV were 
detected in specimen types not previously reported. These 
observations expand understanding of the recently identifi ed 
polyomaviruses and the tissue and organ systems they may 
infect and suggest possible modes of transmission. Further 
studies to defi ne their possible roles in human diseases are 
needed.
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Table 2. Polyomaviruses detected among specimens from children undergoing transplants, USA, 2008–2010* 
Virus Specimen type Transplant Ct Patient ID Date of collection, time elapsed from transplant 
HPyV6 Feces BMT 32.19 3011 2012 Jun 6, 1 mo after 
HPyV6 NP Heart 36.13 4005 2010 Nov 25, 7 mo after 
HPyV6 Feces Lung 36.95 5001 2010 Aug 17, 1 mo after 
HPyV7 NP Liver 34.57 1002 2009 Jun 16, 7 mo after 
HPyV7 Urine Liver 36.54 1002 2009 Jul 15, 8 mo after 
HPyV9 Urine Liver 36.72 1009 2010 Feb 9, 1 wk after 
KIPyV NP BMT 16.28 3001 2009 Jul 7, 3 mo after 
KIPyV NP BMT 36.07 3001 2009 May 19, 1 mo after 
KIPyV NP BMT 33.37 3008 2009 Nov 12, before 
KIPyV NP BMT 31.04 3009 2010 Jul 3, 6 mo after 
MCPyV NP BMT 36.29 3011 2010 Apr 15, before 
MCPyV Feces BMT 34.56 3011 2010 Jul 2, 2 mo after 
TSPyV NP Heart 32.98 4001 2009 May 29, 1 wk after 
TSPyV NP Heart 30.74 4001 2009 Jun 18, 1 mo after 
TSPyV Feces Heart 33.89 4001 2009 May 29, 1 wk after 
WUPyV NP BMT 36.62 3005 2009 Jul 15, before 
WUPyV NP BMT 28.81 3007 2009 Nov 6, 2 mo after 
JCPyV Plasma BMT 36.12 3011 2010 Aug 24, 3 mo after 
BKPyV Urine BMT 15.83 3010 2010 Apr 15, 1 mo after 
BKPyV Urine Kidney 36.67 2022 2010 Jul 1, 10 mo after 
BKPyV Urine BMT 30.80 3011 2010 Aug 24, 3 mo after 
BKPyV Urine Heart 25.84 4001 2009 Aug 14, 2 mo after 
BKPyV Urine Heart 35.89 4003 2009 Dec 23, 2 mo after 
BKPyV Urine Heart 24.37 4001 2009 Sep 23, 4 mo after 
BKPyV Urine Liver 28.56 1010 2009 Nov 23, 1 wk after 
BKPyV Urine Lung 33.13 5002 2011 May 3, 1 y after 
BKPyV Urine Lung 25.25 5002 2011 Feb 8, 10 mo after 
BKPyV Urine Kidney 9.97 2002 2010 Mar 4, 6 mo after 
BKPyV Urine BMT 30.10 3009 2010 Mar 5, 2 mo after 
BKPyV Urine Liver 22.89 1001 2009 Jan 7, 3 mo after 
BKPyV Urine Kidney 34.41 2002 2010 May 13, 8 mo after 
BKPyV NP Kidney 35.93 2002 2010 Mar 4, 6 mo after 
BKPyV Feces Kidney 33.15 2002 2010 Mar 4, 6 mo after 
BKPyV Feces Liver 33.33 1001 2008 Dec 18, 2 mo after 
BKPyV Feces Liver 34.84 1001 2009 Jan 7, 3 mo after 
*Ct, cycle threshold; ID, identification; HPyV, human polyomavirus; BMT, bone marrow transplant; NP, nasopharyngeal; KIPyV, KI polyomavirus; 
MCPyV, Merkel cell polyomavirus; TSPyV, trichodysplasia spinulosa polyomavirus; WUPyV, WU polyomavirus; JCPyV, JC polyomavirus; BKPyV, BK 
polyomavirus 
Figure. Samples tested for TSV (trichodysplasia spinulosa 
polyomavirus) during May–June 2009 from patient 4001, a 13-year-
old heart transplant recipient at St. Louis Children’s Hospital, 
St. Louis, Missouri, USA. Samples tested at each time point are 
indicated by white squares. Black squares represent positive 
samples. NP, nasopharyngeal.
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Feltkamp for the TSPyV-positive control and Christopher 
Buck for the HPyV6-, HPyV7-, and MCPyV-positive controls 
(AddGene plasmids 24727–24729, respectively; addgene.org).
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